proteomics

A limited set of plasma proteins identified 18 solid tumors in all major human organs.

An ingenious chemical labeling strategy offers solutions to enhancing throughput in mass spectrometry analysis.

Slight modifications to glycoproteins reveal critical insights into disease onset, state, and progression, making them a wellspring for biomarker discovery. 

Multiomics data analysis identified structural mutations in tumor genomes with important implications for cancer treatment.

People with myalgic encephalomyelitis/chronic fatigue syndrome can wait years for diagnoses; biomolecular tests are finally in development.

Advances in computation and artificial intelligence help scientists identify novel antibiotics encoded within human proteins and create new ones.

While some pediatric brain cancers have known genetic causes, many do not. Three-dimensional profiling revealed new disease mechanisms and drug targets.

Advances in data integration enable scientists to combine multiomics data and a patient’s clinical record to develop precision medicine approaches for treating disease.

COVID-19 has gotten a little better at infecting cells and dodging antibodies with each set of mutations in new variants. Omicron is the best at dodging antibodies, but its modified structure sacrificed virulence for antibody resistance.